New survival standards for advanced melanoma
Abstract
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.
Journal details
Journal British Journal of Cancer
Volume 122
Issue number 9
Pages 1275-1276
Available online
Publication date
Full text links
Publisher website (DOI) 10.1038/s41416-020-0738-5
Europe PubMed Central 32063602
Pubmed 32063602
Keywords
Related topics
Type of publication